SearcharxivSearch

arXiv subjects

Mauro Gasparini

Publications and source records attributed to Mauro Gasparini.

7 recordsLinked to original sources

On the interplay between prior weight and variance of the robustification component in Robust Mixture Prior Bayesian Dynamic Borrowing approach

Robust Mixture Prior (RMP) is a popular Bayesian dynamic borrowing method, which combines an informative historical distribution with a less informative component (referred as robustification component) in a mixture prior to enhance the efficiency of hybrid-control randomized trials. Current practice typically focuses solely on the selection of the prior weight that governs the relative influence of these two components, often fixing the variance of the robustification component to that of a single observation. In this study we demonstrate that the performance of RMPs critically depends on the joint selection of both weight and variance of the robustification component. In particular, we show that a wide range of weight-variance pairs can yield practically identical posterior inferences (in particular regions of the parameter space) and that large variance robust components may be employed without incurring in the so called Lindley's paradox. We further show that the use of large variance robustification components leads to improved asymptotic Type I error control and enhanced robustness of the RMP to the specification of the location parameter of the robustification component. Finally, we leverage these theoretical results to propose a novel and practical hyper-parameter elicitation routine.

stat.ME

Estimating the optimal time to perform a PET-PSMA exam in prostatectomized patients based on data from clinical practice

Prostatectomized patients are at risk of resurgence, and for this reason, during a follow-up period, they are monitored for Prostate Specific Antigen (PSA) growth, an indicator of tumor progression. The presence of tumors can be evaluated with an expensive exam, called Positron Emission Tomography with Prostate-Specific Membrane Antigen (PET-PSMA). To justify the high cost of the PET-PSMA and, at the same time, to contain the risk for the patient, this exam should be recommended only when the evidence of tumor progression is strong. With the aim of estimating the optimal time to recommend the exam based on the patient's history and collected data, we build a hierarchical Bayesian model that describes, jointly, the PSA growth curve and the probability of a positive PET-PSMA. With our proposal we process all past and present information about the patients PSA measurement and PET-PSMA results, in order to give an informed estimate of the optimal time, improving current practice.

stat.ME

Improving Bayesian estimation of Vaccine Efficacy

A full Bayesian approach to the estimation of Vaccine Efficacy is presented, which is an improvement over the currently used exact method conditional on the total number of cases. As an example, we reconsider the statistical sections of the BioNTech/Pfizer protocol, which in 2020 has led to the first approved anti-Covid-19 vaccine.

stat.ME

On the definition of a concentration function relevant to the ROC curve

This is a reader's reaction to a recent paper by E. Schechtman and G. Schechtman (Metron, 2019) about the correct definition of a concentration function for the diagnostic, i.e. supervised classification, problem. We propose and motivate a different definition and refer to the relevant literature.

stat.ME

Proper likelihood ratio based ROC curves for general binary classification problems

Everybody writes that ROC curves, a very common tool in binary classification problems, should be optimal, and in particular concave, non-decreasing and above the 45-degree line. Everybody uses ROC curves, theoretical and especially empirical, which are not so. This work is an attempt to correct this schizophrenic behavior. Optimality stems from the Neyman-Pearson lemma, which prescribes using likelihood-ratio based ROC curves. Starting from there, we give the most general definition of a likelihood-ratio based classification procedure, which encompasses finite, continuous and even more complex data types. We point out a strict relationship with a general notion of concentration of two probability measures. We give some nontrivial examples of situations with non-monotone and non-continuous likelihood ratios. Finally, we propose the ROC curve of a likelihood ratio based Gaussian kernel flexible Bayes classifier as a proper default alternative to the usual empirical ROC curve.

stat.ME

Loss Functions in Restricted Parameter Spaces and Their Bayesian Applications

Squared error loss remains the most commonly used loss function for constructing a Bayes estimator of the parameter of interest. However, it can lead to sub-optimal solutions when a parameter is defined in a restricted space. It can also be an inappropriate choice in the context when an extreme overestimation and/or underestimation results in severe consequences and a more conservative estimator is preferred. We advocate a class of loss functions for parameters defined on restricted spaces which infinitely penalize boundary decisions like the squared error loss does on the real line. We also recall several properties of loss functions such as symmetry, convexity, and invariance. We propose generalizations of the squared error loss function for parameters defined on the positive real line and on an interval. We provide explicit solutions for corresponding Bayes estimators and discuss multivariate extensions. {Four} well-known Bayesian estimation problems are used to demonstrate inferential benefits the novel Bayes estimators can provide in the context of restricted estimation.

math.ST

Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents

Drug combination trials are increasingly common nowadays in clinical research. However, very few methods have been developed to consider toxicity attributions in the dose escalation process. We are motivated by a trial in which the clinician is able to identify certain toxicities that can be attributed to one of the agents. We present a Bayesian adaptive design in which toxicity attributions are modeled via Copula regression and the maximum tolerated dose (MTD) curve is estimated as a function of model parameters. The dose escalation algorithm uses cohorts of two patients, following the continual reassessment method (CRM) scheme, where at each stage of the trial, we search for the dose of one agent given the current dose of the other agent. The performance of the design is studied by evaluating its operating characteristics when the underlying model is either correctly specified or misspecified. We show that this method can be extended to accommodate discrete dose combinations.

stat.ME